Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy
- 15 March 1991
- Vol. 67 (6) , 1525-1531
- https://doi.org/10.1002/1097-0142(19910315)67:6<1525::aid-cncr2820670611>3.0.co;2-8
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapseCancer, 1989
- Management of Invasive Bladder NeoplasmsPublished by Springer Nature ,1989
- Pre-emptive (Neo-adjuvant) Chemotherapy Prior to Radical Radiotherapy for Fit Septuagenarians with Bladder Cancer: Age Itself is not a Contra-indicationBritish Journal of Urology, 1988
- M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the UrotheliumJournal of Urology, 1988
- Chemotherapy of urothelial tract tumorsCancer, 1987
- Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the UrotheliumJournal of Urology, 1985
- Theory and Applications of Hazard Plotting for Censored Failure DataTechnometrics, 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958